Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies?

touchEXPERT FOCUS for touchHAEMATOLOGY and touchONCOLOGY Listen to a series of short expert interviews on the role of B-cell maturation antigen (BCMA)-directed therapies in relapsed/refractory multiple myeloma (RRMM). The faculty discuss patient selection, treatment tailoring and strategies to manage side effects, providing practical guidance for integrating BCMA-targeting approaches into care. The experts Prof. Jesús San Miguel, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain Prof. Pieter Sonneveld, Erasmus University Medical Center, Rotterdam, The Netherlands Dr Francesca Gay, University of Torino, Italy This touchPODCAST is for HCPs outside of the USA. This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our websites: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com